FDA approves Merck’s first oral PCSK9 inhibitor, marking a first for the drug class

The U.S. Food and Drug Administration has granted approval to Merck for its oral PCSK9 inhibitor, the first drug of this type to receive such clearance.

The approval represents a milestone because PCSK9 therapies have previously been limited to injectable forms, and an oral option could broaden patient access and convenience.

In related biotech news, prediction‑market platform Kalshi announced it will begin offering bets on clinical trial outcomes and FDA decisions, partnering with AppliedXL to select initial markets.